72 related articles for article (PubMed ID: 11904783)
1. Outcomes and costs of febrile neutropenia: adventures in the science and art of treatment choices.
Elting LS; Cantor SB
Support Care Cancer; 2002 Apr; 10(3):189-96. PubMed ID: 11904783
[TBL] [Abstract][Full Text] [Related]
2. Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: A randomized, prospective study.
Ahmed N; El-Mahallawy HA; Ahmed IA; Nassif S; El-Beshlawy A; El-Haddad A
Pediatr Blood Cancer; 2007 Nov; 49(6):786-92. PubMed ID: 17366527
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of outpatient management for febrile neutropenia in children with cancer.
Teuffel O; Amir E; Alibhai SM; Beyene J; Sung L
Pediatrics; 2011 Feb; 127(2):e279-86. PubMed ID: 21220399
[TBL] [Abstract][Full Text] [Related]
4. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection.
Santolaya ME; Alvarez AM; Avilés CL; Becker A; Cofré J; Cumsille MA; O'Ryan ML; Payá E; Salgado C; Silva P; Tordecilla J; Varas M; Villarroel M; Viviani T; Zubieta M
J Clin Oncol; 2004 Sep; 22(18):3784-9. PubMed ID: 15365075
[TBL] [Abstract][Full Text] [Related]
5. Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain.
Mayordomo JI; López A; Viñolas N; Castellanos J; Pernas S; Domingo Alonso J; Frau A; Layola M; Antonio Gasquet J; Sánchez J;
Curr Med Res Opin; 2009 Oct; 25(10):2533-42. PubMed ID: 19722781
[TBL] [Abstract][Full Text] [Related]
6. Estimating resource use and cost of prophylactic management of neutropenia with filgrastim.
Annemans L; Van Overbeke N; Standaert B; Van Belle S
J Nurs Manag; 2005 May; 13(3):265-74. PubMed ID: 15819840
[TBL] [Abstract][Full Text] [Related]
7. Cancer-associated neutropenic fever: clinical outcome and economic costs of emergency department care.
Courtney DM; Aldeen AZ; Gorman SM; Handler JA; Trifilio SM; Parada JP; Yarnold PR; Bennett CL
Oncologist; 2007 Aug; 12(8):1019-26. PubMed ID: 17766662
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer.
Timmer-Bonte JN; Adang EM; Smit HJ; Biesma B; Wilschut FA; Bootsma GP; de Boo TM; Tjan-Heijnen VC
J Clin Oncol; 2006 Jul; 24(19):2991-7. PubMed ID: 16682725
[TBL] [Abstract][Full Text] [Related]
9. A cost analysis of febrile neutropenia management in Australia: ambulatory v. in-hospital treatment.
Lingaratnam S; Worth LJ; Slavin MA; Bennett CA; Kirsa SW; Seymour JF; Dalton A; Koczwara B; Prince HM; O'Reilly M; Mileshkin L; Szer J; Thursky KA
Aust Health Rev; 2011 Nov; 35(4):491-500. PubMed ID: 22126955
[TBL] [Abstract][Full Text] [Related]
10. Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia.
Shehab N; DePestel DD; Mackler ER; Collins CD; Welch K; Erba HP
Pharmacotherapy; 2007 Jul; 27(7):970-9. PubMed ID: 17594202
[TBL] [Abstract][Full Text] [Related]
11. Time to clinical response: an outcome of antibiotic therapy of febrile neutropenia with implications for quality and cost of care.
Elting LS; Rubenstein EB; Rolston K; Cantor SB; Martin CG; Kurtin D; Rodriguez S; Lam T; Kanesan K; Bodey G
J Clin Oncol; 2000 Nov; 18(21):3699-706. PubMed ID: 11054443
[TBL] [Abstract][Full Text] [Related]
12. Pharmacoeconomic analysis of empirical therapy with ceftazidime alone or combination antibiotics for febrile neutropenia in cancer patients.
Dranitsaris G; Tran TM; McGeer A; Narine L
Pharmacoeconomics; 1995 Jan; 7(1):49-62. PubMed ID: 10155293
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of myeloid growth factors in cancer chemotherapy.
Lyman GH; Kuderer NM
Curr Hematol Rep; 2003 Nov; 2(6):471-9. PubMed ID: 14561391
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness evaluation of voriconazole versus liposomal amphotericin B as empirical therapy for febrile neutropenia in Australia.
Al-Badriyeh D; Liew D; Stewart K; Kong DC
J Antimicrob Chemother; 2009 Jan; 63(1):197-208. PubMed ID: 19001450
[TBL] [Abstract][Full Text] [Related]
15. Outpatient management of febrile neutropenia: time to revise the present treatment strategy.
Carstensen M; Sørensen JB
J Support Oncol; 2008; 6(5):199-208. PubMed ID: 18551855
[TBL] [Abstract][Full Text] [Related]
16. A cost--utility analysis of treatment options for inguinal hernia in 1,513,008 adult patients.
Stylopoulos N; Gazelle GS; Rattner DW
Surg Endosc; 2003 Feb; 17(2):180-9. PubMed ID: 12415334
[TBL] [Abstract][Full Text] [Related]
17. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
Griebsch I; Coast J; Brown J
Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
[TBL] [Abstract][Full Text] [Related]
18. Cefepime versus ticarcillin and clavulanate potassium and aztreonam for febrile neutropenia therapy in high-dose chemotherapy patients.
Fleming DR; Ziegler C; Baize T; Mudd L; Goldsmith GH; Herzig RH
Am J Clin Oncol; 2003 Jun; 26(3):285-8. PubMed ID: 12796602
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of herpes simplex virus testing and treatment strategies in febrile neonates.
Caviness AC; Demmler GJ; Swint JM; Cantor SB
Arch Pediatr Adolesc Med; 2008 Jul; 162(7):665-74. PubMed ID: 18606938
[TBL] [Abstract][Full Text] [Related]
20. The cost-effectiveness of empirical antibiotic treatments for high-risk febrile neutropenic patients: A decision analytic model.
Tori K; Tansarli GS; Parente DM; Kalligeros M; Ziakas PD; Mylonakis E
Medicine (Baltimore); 2020 May; 99(20):e20022. PubMed ID: 32443305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
